March 2016

New Product - Xifaxan

Xifaxan 200 mg (rifaximin) is a nonaminoglycoside semisynthetic, nonsystemic antibiotic derived from rifamycin SV. Rifaximin acts by binding to the beta‑subunit of bacterial DNA dependent RNA polymerase resulting in inhibition of bacterial RNA synthesis. Rifaximin has a broad antimicrobial spectrum against most of the Gram positive and Gram negative, aerobic and anaerobic bacteria responsible for intestinal infections. Xifaxan 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travellers’ diarrhoea caused by noninvasive strains of Escherichia coli. Xifaxan 200 mg is contraindicated with hypersensitivity to any of the rifamycin antimicrobial agents. Xifaxan 200 mg tablets are available in packs of 9’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au